about
Profile of certolizumab and its potential in the treatment of psoriatic arthritisPharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapiesMaking the next steps in psoriatic arthritis management: current status and future directionsMeasures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds EnTumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literatureManaging patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasisOptimal management of dactylitis in patients with psoriatic arthritisRecent advances in understanding and managing psoriatic arthritisPsoriasis and comorbid diseases: Implications for management.International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trialsEffectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world.Economic impact of biologic utilization patterns in patients with psoriatic arthritisEffectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.Case report: Infliximab treatment in two Chinese patients with psoriatic arthritis.Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs.Use of biologic agents in combination with other therapies for the treatment of psoriasisSpondyloarthritides: evolving therapiesPsoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasisQualifying unmet needs and improving standards of care in psoriatic arthritis.Management of arthropathy in inflammatory bowel diseases.Downregulation of immunoglobulin-like transcript-4 (ILT4) in patients with psoriatic arthritis.Evidence-based recommendations on the role of dermatologists in the diagnosis and management of psoriatic arthritis: systematic review and expert opinion.Treatment (biotherapy excluded) of psoriatic arthritis: an appraisal of methodological quality of international guidelines.Diagnosing Psoriatic Arthritis from the Dermatologist's View.Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany.A randomized placebo-controlled trial of methotrexate in psoriatic arthritisThe Epidemiology of Psoriatic Arthritis.Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspectiveAnti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis.Steps in the management of psoriatic arthritis: a guide for clinicians.Clinical potential of apremilast in the treatment of psoriatic arthritisThe skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis.Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis.Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience.Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis.Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis.
P2860
Q22305856-2FB3AECC-C278-49A2-9DC3-B0BE3C54F96CQ26777084-C599DC4C-CA6D-4F37-B4B2-F0372360F04AQ26783506-BF856B55-B943-4D66-8317-3F18056CB742Q26862017-B4D9DA43-02E7-42CC-82EC-2367373510ACQ27012134-3556752D-D5B7-4C7D-BF99-47C687083D73Q27693878-0C593485-9802-493E-9973-FDEC98FDF716Q28072557-705ADF7D-FFE7-4D93-A9C1-4520E82A6F18Q28076527-DF00123C-E78B-41F6-9E54-10B5DC7ED459Q30235888-156DF508-3AFA-45D2-9F4F-2F9F4D2ABAA7Q30841346-596F7979-A116-4CAA-9B1A-C9DD2FFBBFB6Q33566374-7D38A316-CEDC-4CBD-A13F-F5902131936EQ33747197-AF4E5FB9-E4F8-481B-A4C5-C0FDC8140FB1Q33840422-C73890D1-40BA-4026-8193-CEE22288811CQ34027624-B4084812-5035-47B4-BCA8-CA953314C82BQ34176748-A0013627-9400-4B38-993C-6894E2FE3D62Q34267352-5543BFE8-B1DB-40CF-8400-E77D657AEF9AQ34553755-1827C39A-F11F-4155-9A72-09A8E25B5DBAQ34613907-696E8F7E-6F01-4CEC-879A-B091BC089DACQ34643790-BE163709-2991-4224-A7B2-8D6AEC3EAFF0Q34803582-16A2AC05-EA69-4181-BD1A-0610B297DD9AQ35091366-8BCD47AC-72A7-4B37-A7CD-5DCC606FB1A2Q35133638-A84646D6-F675-4497-9848-EC68D77AB3FFQ35199592-74DFBE24-DFA4-41AE-9FD1-B710AE70A6F6Q35199602-5E3537D6-FEE1-4098-97C1-4CB1F9C73092Q35332756-42AECD24-FDDC-4FF6-B5AB-E64CC4C71831Q35819025-2CA534F9-0430-400D-9526-6AEEB81C0ED9Q35851000-693EC56C-D5AD-4FEF-8FA2-FCD95846C066Q36096798-C377E510-C707-4008-ADCC-5F0BEEAE1752Q36175115-7F60AD6A-ED00-42D0-BC23-4E1B00860220Q36439036-C35B5973-3B50-4447-97D3-EE1F2C923BEAQ36479450-36F93172-5B51-461D-9DFC-64E5E43CB519Q36515480-2643C34F-4F8D-4210-B0B2-4EB8AF906273Q37031662-587125D3-D63E-4EF4-A38C-ABBBC23AFB24Q37196596-245E39D2-493B-484F-A5A5-33A3FACB8260Q37301177-80C87EE8-1DF3-4C4E-B885-E5FD8728336AQ37308871-87893699-EFB6-4B5A-BCE0-8696C12538F6Q37453027-19E05DB0-B234-4682-99F8-4537D4082FCFQ37465518-A1177699-E614-4602-A55D-6BC452667C88Q37480069-BF4F4C23-54CE-458D-BF2E-05D098810EA2Q37520856-645651B4-88F2-4674-BD65-8A5A5F8F31CB
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment recommendations for psoriatic arthritis.
@en
Treatment recommendations for psoriatic arthritis.
@nl
type
label
Treatment recommendations for psoriatic arthritis.
@en
Treatment recommendations for psoriatic arthritis.
@nl
prefLabel
Treatment recommendations for psoriatic arthritis.
@en
Treatment recommendations for psoriatic arthritis.
@nl
P2093
P2860
P50
P356
P1476
Treatment recommendations for psoriatic arthritis
@en
P2093
A A Qureshi
A B Gottlieb
A Kavanaugh
C T Ritchlin
D D Gladman
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
N J McHugh
O Fitzgerald
P Helliwell
P2860
P304
P356
10.1136/ARD.2008.094946
P407
P5008
P577
2008-10-24T00:00:00Z